Degreef H
Department of Dermatology, U.Z. St. Rafael, Leuven, Belgium.
Cutis. 1996 Jul;58(1):90-3.
Seventy-one patients with tinea capitis were treated with itraconazole (50 or 100 mg once daily) for a median period of six weeks in an open multicenter study. Many of the patients were children. Of those patients treated with itraconazole 100 mg, 93 percent showed a clinical response at the end of treatment. This increased to 94 percent two months later. The mycologic cure rate at the end of treatment was 57 percent. At the final visit this had increased to 89 percent. Patients taking 50 mg itraconazole also responded to treatment, but to a lesser degree: only 67 percent showed a clinical response at the final visit. The corresponding mycologic cure was 60 percent. Only one patient reported a side effect while taking itraconazole (papular eruption) and it is uncertain whether this was related to treatment. It was concluded that both treatment schedules were effective and safe for children with tinea capitis.
在一项开放性多中心研究中,71例头癣患者接受伊曲康唑治疗(每日1次,50或100毫克),中位治疗期为6周。许多患者为儿童。接受100毫克伊曲康唑治疗的患者中,93%在治疗结束时出现临床反应。两个月后这一比例增至94%。治疗结束时真菌学治愈率为57%。在最后一次随访时,这一比例已增至89%。服用50毫克伊曲康唑的患者也对治疗有反应,但程度较轻:最后一次随访时只有67%出现临床反应。相应的真菌学治愈率为60%。只有1例患者在服用伊曲康唑时报告有副作用(丘疹性皮疹),尚不确定这是否与治疗有关。得出的结论是,两种治疗方案对儿童头癣均有效且安全。